Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect

May 6, 2025
, 4:45 pm

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Eli Lilly is licensing rights to a Phase 1-ready antibody that startup Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders. Lilly’s pipeline has ALS drug candidates from previous deals with QurAlis and Verge Genomics.

The post Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect appeared first on MedCity News.

Leave a Replay

The AI Drug Discovery Boom Is Coming. We Are Not Ready.

Data Integration: The Essential Element in Telemedicine Sustainability

HHS Health IT Innovation Exec Joins INVEST Agenda at Critical Time for the Department

Sign up for our Newsletter

HealthGility provides healthcare organizations with a solution for patient protected health information disclosure and confidentiality that reduces workloads and ensures the safe and secure sharing of sensitive data between different providers.

Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect

Leave a Replay

Related Posts

The AI Drug Discovery Boom Is Coming. We Are Not Ready.

Data Integration: The Essential Element in Telemedicine Sustainability

HHS Health IT Innovation Exec Joins INVEST Agenda at Critical Time for the Department

Follow Us

Sign up for our Newsletter

Our Company

Resources

Connect

© All rights reserved

Contact Us